Novartis Gains European Commission Approval for Itvisma in Broad SMA Population

Novartis has secured European Commission approval for Itvisma® (onasemnogene abeparvovec), an AAV9-based gene replacement therapy now cleared for patients with 5q spinal muscular atrophy aged two years and older, a population scope that no other gene therapy currently covers in the EU. For manufacturing and QA leads, the approval consolidates Novartis's position as the only sponsor holding dual SMA gene therapy authorisations in Europe, alongside the already-approved Zolgensma for patients under two.

The fixed, weight- and age-independent single dose presents a distinct GMP profile from the small-molecule and antisense oligonucleotide alternatives on the market. Cold-chain integrity, viral vector batch consistency, and sterility assurance across a broader patient weight range will be central operational considerations as sites scale to meet EU demand. The one-time dosing model removes the repeat-administration burden but concentrates quality risk into a single administration event, raising the stakes for in-process controls and final product release testing.

The EC decision rests on data from the registrational STEER study, supported by the Phase IIIb STRENGTH and Phase I/II STRONG studies. STEER recorded a statistically significant 2.39-point improvement on the Hammersmith Functional Motor Scale (HFMSE), with effects sustained over 52 weeks. Both STEER and STRENGTH demonstrated clinically meaningful benefit in treatment-naïve and pre-treated patients, a finding that broadens the eligible population beyond first-line use and adds complexity to post-approval pharmacovigilance obligations under EU GVP Module VI.

SMA affects an estimated 1 to 2 per 100,000 people globally, with an incidence of roughly 1 in 10,000 live births. The SMN1 gene mutation disrupts SMN protein production, causing irreversible motor neuron loss. Itvisma delivers a functional SMN1 gene copy via AAV9 vector, targeting the root genetic cause rather than compensating through SMN2 splicing modulation as some existing therapies do. That mechanistic difference will inform how QA teams approach comparability assessments if manufacturing sites or processes are supplemented to meet expanded EU volume requirements.

Regulatory affairs teams at competing gene therapy sponsors should note that the approval establishes a clinical and regulatory precedent for broader age-range labelling in EU gene replacement programmes, potentially influencing how the EMA frames future benefit-risk assessments for similar modalities. Access timelines across individual EU member states will depend on national health technology assessment outcomes, which historically vary in pace and reimbursement criteria for high-cost one-time therapies.

The measurable outcome to track is whether Novartis can demonstrate consistent vector yield and release specifications across the expanded patient weight range as commercial supply scales to meet the newly authorised EU indication.

Source: Novartis via GlobeNewswire, 2 July 2026.